Semaglutide Linked to Lower Rates of Cannabis Use Disorder in Large Health Records Study
People prescribed semaglutide had 40-56% lower risk of developing cannabis use disorder and 38% lower risk of relapse compared to those on other medications for obesity or diabetes.
Quick Facts
What This Study Found
In patients with obesity, semaglutide was associated with lower risk of new CUD (HR: 0.56) and recurrent CUD (HR: 0.62) versus non-GLP-1RA anti-obesity medications. Similar reductions appeared in patients with type 2 diabetes for new CUD (HR: 0.40) and recurrent CUD (HR: 0.66).
Key Numbers
Obesity cohort: incident CUD HR 0.56 (95% CI: 0.42-0.75), recurrent CUD HR 0.62 (95% CI: 0.46-0.84). T2D cohort: incident CUD HR 0.40 (95% CI: 0.29-0.56), recurrent CUD HR 0.66 (95% CI: 0.42-1.03). Consistent reductions across gender, age, and race strata. Sample: 85,223 obesity patients, 596,045 T2D patients.
How They Did This
Retrospective cohort study using electronic health records from the TriNetX Analytics Network (~105.3 million patients from 61 US healthcare organizations). Compared propensity-score matched cohorts: 85,223 patients with obesity prescribed semaglutide vs non-GLP-1RA anti-obesity medications, replicated in 596,045 patients with T2D. 12-month follow-up.
Why This Research Matters
There are currently no FDA-approved medications for cannabis use disorder despite more than 45 million US users, one-third of whom meet criteria for CUD. If semaglutide's apparent protective effect is confirmed in randomized trials, it could represent the first pharmacological treatment option for this common condition.
The Bigger Picture
GLP-1 receptor agonists like semaglutide appear to affect reward circuitry beyond their metabolic targets. Preclinical studies show they reduce consumption of alcohol, nicotine, and now potentially cannabis, suggesting these drugs may broadly modulate addictive behaviors through appetite and reward pathways.
What This Study Doesn't Tell Us
Retrospective design with electronic health records cannot establish causation. CUD diagnosis in EHRs may undercount actual cases. Propensity score matching reduces but does not eliminate confounding. The T2D recurrent CUD result did not reach statistical significance (CI crossed 1.0).
Questions This Raises
- ?What is the mechanism by which semaglutide reduces cannabis use disorder risk?
- ?Would the effect persist if semaglutide is discontinued?
- ?Are other GLP-1 receptor agonists similarly protective?
Trust & Context
- Key Stat:
- 56% lower risk of new cannabis use disorder in obesity patients on semaglutide
- Evidence Grade:
- Moderate: very large sample with propensity score matching and replication across two populations, but retrospective EHR design cannot prove causation.
- Study Age:
- 2024 study.
- Original Title:
- Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.
- Published In:
- Molecular psychiatry, 29(8), 2587-2598 (2024)
- Authors:
- Wang, William, Volkow, Nora D(10), Berger, Nathan A, Davis, Pamela B, Kaelber, David C, Xu, Rong
- Database ID:
- RTHC-05798
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
How might semaglutide reduce cannabis use disorder?
Semaglutide acts on GLP-1 receptors, which are present in brain reward centers. Preclinical research suggests GLP-1 receptor agonists reduce the rewarding effects of multiple substances by modulating dopamine pathways involved in addiction.
Is semaglutide approved for treating cannabis use disorder?
No. There are currently no FDA-approved medications for CUD. This observational study provides preliminary evidence that warrants randomized clinical trials to determine if semaglutide could become the first such treatment.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-05798APA
Wang, William; Volkow, Nora D; Berger, Nathan A; Davis, Pamela B; Kaelber, David C; Xu, Rong. (2024). Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.. Molecular psychiatry, 29(8), 2587-2598. https://doi.org/10.1038/s41380-024-02498-5
MLA
Wang, William, et al. "Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.." Molecular psychiatry, 2024. https://doi.org/10.1038/s41380-024-02498-5
RethinkTHC
RethinkTHC Research Database. "Association of semaglutide with reduced incidence and relaps..." RTHC-05798. Retrieved from https://rethinkthc.com/research/wang-2024-association-of-semaglutide-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.